Aquestive Therapeutics

Aquestive Therapeutics company information, Employees & Contact Information

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut Syndrome. Our licensees market their products in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.

Company Details

Employees
147
Address
30 Technology Drive, Warren,new Jersey 07059,united States
Phone
908-941-1900
Email
sa****@****ive.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Warren, New Jersey
Looking for a particular Aquestive Therapeutics employee's phone or email?

Aquestive Therapeutics Questions

News

Aquestive Therapeutics to Report Third Quarter 2025 - GlobeNewswire

Aquestive Therapeutics to Report Third Quarter 2025 GlobeNewswire

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™ - GlobeNewswire

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™ GlobeNewswire

Allergen-related symptoms resolve within 5 minutes with epinephrine sublingual film - Healio

Allergen-related symptoms resolve within 5 minutes with epinephrine sublingual film Healio

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewswire

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences GlobeNewswire

Aquestive Therapeutics Announces that FDA Will Not Require - GlobeNewswire

Aquestive Therapeutics Announces that FDA Will Not Require GlobeNewswire

Aquestive Therapeutics Announces $75M Strategic Funding - GlobeNewswire

Aquestive Therapeutics Announces $75M Strategic Funding GlobeNewswire

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock - GlobeNewswire

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock GlobeNewswire

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - GlobeNewswire

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer GlobeNewswire

Aquestive Therapeutics Announces FDA Acceptance of New Drug - GlobeNewswire

Aquestive Therapeutics Announces FDA Acceptance of New Drug GlobeNewswire

Aquestive Therapeutics Announces Positive Topline PK - GlobeNewswire

Aquestive Therapeutics Announces Positive Topline PK GlobeNewswire

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update GlobeNewswire

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update GlobeNewswire

Aquestive Therapeutics: Expect Its Torrid Pace To Relax (Rating Downgrade) (NASDAQ:AQST) - Seeking Alpha

Aquestive Therapeutics: Expect Its Torrid Pace To Relax (Rating Downgrade) (NASDAQ:AQST) Seeking Alpha

Aquestive Therapeutics Announces $75M Strategic Funding - citybiz

Aquestive Therapeutics Announces $75M Strategic Funding citybiz

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update GlobeNewswire

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives - GlobeNewswire

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives GlobeNewswire

Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst (AQST) - Seeking Alpha

Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst (AQST) Seeking Alpha

Anaphylm Sublingual Film Achieves Rapid Resolution of Allergen-Related Symptoms - HCPLive

Anaphylm Sublingual Film Achieves Rapid Resolution of Allergen-Related Symptoms HCPLive

Anaphylm sublingual film demonstrates positive results in pediatric patients with severe allergic reactions - Contemporary Pediatrics

Anaphylm sublingual film demonstrates positive results in pediatric patients with severe allergic reactions Contemporary Pediatrics

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum on I&I and Metabolism - Nasdaq

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum on I&I and Metabolism Nasdaq

Aquestive Therapeutics and Haisco Pharmaceutical Group - GlobeNewswire

Aquestive Therapeutics and Haisco Pharmaceutical Group GlobeNewswire

FDA accepts NDA for epinephrine sublingual film to treat type 1 allergic reactions - Contemporary Pediatrics

FDA accepts NDA for epinephrine sublingual film to treat type 1 allergic reactions Contemporary Pediatrics

ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both - Seeking Alpha

ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both Seeking Alpha

Aquestive Therapeutics Receives FDA Fast Track Designation - GlobeNewswire

Aquestive Therapeutics Receives FDA Fast Track Designation GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data from - GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data from GlobeNewswire

Aquestive Therapeutics Announces $8.5 Million Registered Direct Offering - citybiz

Aquestive Therapeutics Announces $8.5 Million Registered Direct Offering citybiz

Sublingually administered epinephrine continues to show promise - Healio

Sublingually administered epinephrine continues to show promise Healio

Aquestive Therapeutics Reports Positive Topline Data from - GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data from GlobeNewswire

AQST - Aquestive Therapeutics Latest Stock News & Market Updates - Stock Titan

AQST - Aquestive Therapeutics Latest Stock News & Market Updates Stock Titan

Aquestive Therapeutics (AQST) Stock Price, News & Analysis - MarketBeat

Aquestive Therapeutics (AQST) Stock Price, News & Analysis MarketBeat

AQST Stock Price and Chart — NASDAQ:AQST - TradingView

AQST Stock Price and Chart — NASDAQ:AQST TradingView

Top Aquestive Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant